- Home
- FRBA vs NGNE Comparison
FRBA vs NGNE Comparison
Compare FRBA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRBA
- NGNE
- Stock Information
- Founded
- FRBA 2007
- NGNE 2003
- Country
- FRBA United States
- NGNE United States
- Employees
- FRBA N/A
- NGNE N/A
- Industry
- FRBA Major Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FRBA Finance
- NGNE Health Care
- Exchange
- FRBA Nasdaq
- NGNE Nasdaq
- Market Cap
- FRBA 352.3M
- NGNE 352.4M
- IPO Year
- FRBA N/A
- NGNE N/A
- Fundamental
- Price
- FRBA $13.99
- NGNE $23.11
- Analyst Decision
- FRBA Buy
- NGNE Strong Buy
- Analyst Count
- FRBA 1
- NGNE 6
- Target Price
- FRBA $17.00
- NGNE $60.80
- AVG Volume (30 Days)
- FRBA 53.6K
- NGNE 433.1K
- Earning Date
- FRBA 01-22-2025
- NGNE 11-18-2024
- Dividend Yield
- FRBA 1.70%
- NGNE N/A
- EPS Growth
- FRBA 54.36
- NGNE N/A
- EPS
- FRBA 1.60
- NGNE N/A
- Revenue
- FRBA $123,433,000.00
- NGNE $925,000.00
- Revenue This Year
- FRBA N/A
- NGNE N/A
- Revenue Next Year
- FRBA $5.07
- NGNE N/A
- P/E Ratio
- FRBA $8.76
- NGNE N/A
- Revenue Growth
- FRBA 34.10
- NGNE N/A
- 52 Week Low
- FRBA $11.20
- NGNE $14.44
- 52 Week High
- FRBA $15.87
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- FRBA 36.72
- NGNE 39.63
- Support Level
- FRBA $13.73
- NGNE $21.34
- Resistance Level
- FRBA $14.44
- NGNE $23.89
- Average True Range (ATR)
- FRBA 0.35
- NGNE 1.97
- MACD
- FRBA -0.11
- NGNE 0.84
- Stochastic Oscillator
- FRBA 19.33
- NGNE 22.67
About FRBA First Bank
First Bank is a full-service commercial bank, with an emphasis on providing personal and business financial services to individuals and small to mid-sized businesses. The Bank provides its customers with a variety of financial services targeting all segments of the retail and corporate market. Its Business Banking offers commercial deposit accounts, business loans, online banking, and cash management.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.